Skip to main content
SpringerLink
Log in

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

  • Chapter
Life-Threatening Dermatoses and Emergencies in Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bastuji-Garin S, Rzany B, Stern RS et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92–96

    Article  PubMed  CAS  Google Scholar 

  2. Hebra von F (1866) Erythema exsudativum multiforme. In: Atlas der Hautkrankheiten, Kaiserliche Akademie der Wissenschaften. Wien, Austria, 54–57

    Google Scholar 

  3. Lyell A (1956) Toxic epidermal necrolysis: An eruption resembling scalding of the skin. Br J Dermatol 68:355–361

    Article  PubMed  CAS  Google Scholar 

  4. Stevens AM, Johnson FC (1922) A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children. Am J Dis Child 24:526–533

    Google Scholar 

  5. Assier H, Bastuji-Garin S, Revuz J et al (1995) Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 131:539–543

    Article  PubMed  CAS  Google Scholar 

  6. Auquier-Dunant A, Mockenhaupt M, Naldi L et al (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 138:1019–1024

    Article  PubMed  Google Scholar 

  7. Rzany B, Hering O, Mockenhaupt M et al (1996) Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 135:6–11

    Article  PubMed  CAS  Google Scholar 

  8. Côté B, Wechsler J, Bastuji-Garin S et al (1995) Clinicopathologic correlation in erythema multiforme and Stevens–Johnson syndrome. Arch Dermatol 131:1268–1272

    Article  PubMed  Google Scholar 

  9. Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. New Eng J Med 331:1272–1285

    Article  PubMed  CAS  Google Scholar 

  10. Sidoroff A, Dunant A, Viboud C et al (2007) Risk factors for acute generalized exanthematous pustulosis (AGEP) – results of a multinational case-control study (EuroSCAR). Br J Dermatol 157:989–996

    Article  PubMed  CAS  Google Scholar 

  11. Ziemer M, Wiesend CL, Vetter R et al (2007) Cutaneous adverse drug reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 143:711–716

    Article  PubMed  CAS  Google Scholar 

  12. Elias PM, Fritsch P, Epstein EH Jr (1977) Staphylococcal scalded skin syndrome: Clinical features, pathogenesis, and recent microbiological and biochemical developments. Arch Dermatol 113:207–219

    Article  PubMed  CAS  Google Scholar 

  13. Kauppinen K (1972) Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides. A clinical study. Acta Derm Venereol 52(Suppl.):68

    Google Scholar 

  14. Roujeau JC, Guillaume JC, Fabre JP et al (1990) Toxic epidermal necrolysis (Lyell's syndrome): Incidence and drug etiology in France, 1981–1985. Arch Dermatol 126:37–42

    Article  PubMed  CAS  Google Scholar 

  15. Schöpf E, Stühmer A, Rzany B et al (1991) Toxic epidermal necrolysis and Stevens–Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 127:839–842

    Article  PubMed  Google Scholar 

  16. Rzany B, Mockenhaupt M, Baur S et al (1996) Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990–1992). Structure and results of a population-based registry. J Clin Epidemiol 49:769–773

    Article  PubMed  CAS  Google Scholar 

  17. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN et al (2001) Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal – results of a case-control study. AIDS 15:1–6

    Article  Google Scholar 

  18. Mockenhaupt M, Messenheimer J, Schlingmann J et al (2005) Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of anti-epileptics. Neurology 64:1134–1138

    PubMed  CAS  Google Scholar 

  19. Roujeau JC, Kelly JP, Naldi L et al (1995) Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Eng J Med 333:1600–1607

    Article  CAS  Google Scholar 

  20. Mockenhaupt M, Viboud C, Dunant A et al (2008) Stevens– Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 128(1):35–44

    Article  PubMed  CAS  Google Scholar 

  21. Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32

    Article  PubMed  Google Scholar 

  22. Correia O, Delgado L, Ramos JP et al (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis: Further evidence of CD8 + lymphocyte involvement. Arch Dermatol 129:466–468

    Article  PubMed  CAS  Google Scholar 

  23. Viard I, Wehrli P, Bullani R et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493

    Article  PubMed  CAS  Google Scholar 

  24. Dietrich A, Kawakubo Y, Rzany B, et al (1995) Low N-acety-lating capacity in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 4:313–316

    Article  PubMed  CAS  Google Scholar 

  25. Nassif A, Bensussan A, Boumsell L et al (2004) Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114(5): 1209–1215

    Article  PubMed  CAS  Google Scholar 

  26. Nassif A, Moslehi H, Le Gouvello S et al (2004) Evaluation of the potential role of cytokines in toxic epidermal necrolysis J Invest Dermatol. 123(5):850–855

    Article  PubMed  CAS  Google Scholar 

  27. Roujeau JC, Huynh TN, Bracq C et al (1987) Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123:1171–1173

    Article  PubMed  CAS  Google Scholar 

  28. Wolkenstein P, Charue D, Laurent P et al (1995) Metabolic predisposition to cutaneous adverse drug reactions: Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 131:544–551

    Article  PubMed  CAS  Google Scholar 

  29. Chung WH, Hung SI, Hong HS et al (2004) A marker for Stevens–Johnson syndrome. Nature 428:486

    Article  PubMed  CAS  Google Scholar 

  30. Lonjou C, Borot N, Sekula P et al (2008) A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom 18(2):99–107

    Article  CAS  Google Scholar 

  31. Lonjou C, Thomas L, Borot N, et al (2006) A marker for Stevens–Johnson syndrome and toxic epidermal necrolysis: Ethnicity matters. Pharmacogenom J 6:265–268

    CAS  Google Scholar 

  32. Roujeau JC, Chosidow O, Saiag P et al (1990) Toxic epidermal necrolysis (Lyell's syndrome). J Am Acad Dermatol 23:1039–1058

    Article  PubMed  CAS  Google Scholar 

  33. Wolkenstein P, Latarje J, Roujeau J et al (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586–1589

    Article  PubMed  CAS  Google Scholar 

  34. Prins C, Kerdel FA, Padilla S et al (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139:26–32

    Article  PubMed  CAS  Google Scholar 

  35. Trent JT, Kirsner RS, Romanelli P et al (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. The University of Miami experience. Arch Dermatol 139:39–43

    Article  PubMed  CAS  Google Scholar 

  36. Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG). Clinical experience to date. Drugs 65(15):2085–2090

    Article  PubMed  CAS  Google Scholar 

  37. Bastuji-Garin S, Fouchard N, Bertocchi M et al (2000) SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153

    Article  PubMed  CAS  Google Scholar 

  38. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefiton mortality or progression. Arch Dermatol 139:33–36

    Article  PubMed  CAS  Google Scholar 

  39. Brown KM, Silver GM, Halerz M et al (2004) Toxic epidermal necrolysis: Does immunoglobulin make a difference? J Burn Care Rehabil 25:81–88

    Article  PubMed  CAS  Google Scholar 

  40. Shortt R, Gomes M, Mittman N et al (2004) Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25:246–255

    Article  PubMed  Google Scholar 

  41. Schneck J, Fagot JP, Sekula P et al (2008) Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58(1):33–40

    Article  PubMed  Google Scholar 

  42. Garcia-Doval I, LeCleach L, Bocquet H et al (2000) Toxic epidermal necrolysis and Stevens–Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136:323–327

    Article  PubMed  CAS  Google Scholar 

  43. Stern RS (2000) Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 136:410

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dokumentationszentrum schwerer Hautreaktionen (DZH), Universitäts-Hautklinik Freiburg, Hauptstrasse 7, Freiburg, 79104, Germany

    Maja Mockenhaupt

Authors
  1. Maja Mockenhaupt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Dermatologie, Centre hospitalier universitaire Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, Créteil, 94010, France

    Jean Revuz  & Laurence Valeyrie-Allanore  & 

  2. Université Paris XII Service de Dermatologie, Centre hospitalier universitaire Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, Créteil, 94010, France

    Jean-Claude Roujeau

  3. Department of Dermatology, Cedars Medical Center, 1400 NW 12 Avenue 6th South, Miami, FL, 33136, USA

    Francisco A. Kerdel

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mockenhaupt, M. (2009). Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. In: Revuz, J., Roujeau, JC., Kerdel, F.A., Valeyrie-Allanore, L. (eds) Life-Threatening Dermatoses and Emergencies in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79339-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79339-7_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79338-0

  • Online ISBN: 978-3-540-79339-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation